"510(k) Summary"

JAN 0'9 2013

Date Prepared:

December 18, 2012

Manufacturer:

Best Medical International, Inc.

7643 Fullerton Road, Springfield, VA 22153

Phone: (703) 451-2378 Fax: (703) 451-4736.

Contact Person:

Dharmendra Thakur

Manager, Quality and Regulatory Affairs

Phone: (703) 451-2378 Ext-162

Fax: (703) 451-4736.

Trade Name:

"Best[®] Localization Needle with I-125 Seed"

Common Name:

Source, Brachytherapy, Radionuclide

Classification name:

Radionuclide Brachytherapy Source (21 CFR 892.5730)

Predicate device:

BrachySciences Radioactive Seed Localization Needle with

AnchorSeed (K111979)

Description:

"Best[®] Localization Needle with I-125 Seed" contains low activity Iodine seed (Best I-125- K912170). The Iodine-125 seed is loaded as loose or as stranded inside the needle. Most commonly, 18 gauge 5cm to 20 cm needles are used as a breast localization needle to facilitate the introduction of radionuclide seed into the breast cancer area. The devices are packaged in a pouch with label and provided sterile.

Intended Use:

Best[®] Localization Needle with I-125 Seed, is a device intended to be used with or without absorbable strands to facilitate the introduction of a radionuclide (Iodine-125) seed to non palpable breast lesions for excision.

Summary of Substantial

Equivalence:

The technological characteristic and intended use of Best[®] Localization Needle with I-125 Seed is similar to the predicate device (BrachySciences Radioactive Seed Localization Needle with AnchorSeed). In summary, "Best[®] Localization Needle with I-125 Seed" as described in this submission is substantially equivalent to the predicate device.

7643 Fullerton Road, Springfield, VA 22153 USA phone 703 451 2378 800 336 4970 fax 703 451 5228 www.bestmedical.com





Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002

C/O Mr. Dharmendra Thakur Manager, Quality and Regulatory Affairs Best Medical International 7643 Fullerton Road SPRINGFIELD VA 22153

January 9, 2013

Re: K122704

Trade/Device Name: Best® Localization Needle with I-125 seed

Regulation Number: 21 CFR 892.5730

Regulation Name: Radionuclide brachytherapy source

Regulatory Class: II Product Code: KXK Dated: November 9, 2012 Received: November 13, 2012

Dear Mr. Thakur:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Janine M. Morris

Director, Division of Radiological Health

Office of In Vitro Diagnostics and Radiological Health

Michael D. OHara

Center for Devices and Radiological Health

Enclosure

Indications for Use

10(k) Number (if known): K122704
Device Name: Best Localization Needle with I-125 Seed
ndications for Use:
The device is indicated as "single-use sterile device". Best [®] Localization Needle with I-125 Seed is indicated in the use for Breast Localization purpose under the direct supervision of a qualified physician.
Prescription Use X AND/OR Over-The-Counter Use (21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)
(Division Sign Off) Division of Radiological Health Office of In Vitro Diagnostic and Radiological Health
510(k)K122704
Page 1 of